In the rapidly evolving landscape of medical cannabis in the UK, patients and clinics alike must navigate a complex regulatory environment. One term increasingly encountered is MDT review — short for multidisciplinary team review. But what exactly does it mean? Why is it relevant for cannabis clinics? And how does it relate to patient safety, legal prescribing, and specialist competence?
In this article, I’ll break down what an MDT review is, why it's important, particularly when dealing with complex conditions, and what responsibilities cannabis clinics have under UK healthcare regulations. I’ll reference trusted sources such as the Care Quality Commission (CQC) and the General Medical Council (GMC) Specialist Register to provide clarity for patients and providers alike.
What Is an MDT Review?
I remember a project where was shocked by the final bill.. An MDT review is a collaborative case review process involving professionals from multiple disciplines. The multidisciplinary team (MDT) typically includes doctors, nurses, pharmacists, therapists, and sometimes social workers or psychologists, depending on the patient’s needs.
Its purpose is to ensure comprehensive assessment and holistic management of patients, especially those with complex or chronic conditions. The team discusses diagnostic findings, treatment plans, and ongoing care strategies to optimize patient outcomes.
How Does an MDT Review Work?
Case Presentation: The lead clinician presents the patient’s history, diagnosis, and treatment progress. Multi-Professional Input: Team members share insights based on their expertise, highlighting risks, options, and potential side-effects. Planning: The team collaborates on next steps, adjusting medication, referring to specialists, or arranging further investigations. Documentation: Recommendations and decisions are recorded in the patient’s notes for accountability and continuity.Here's what kills me: this process is standard practice in many nhs settings, such as oncology or complex neurological care. It ensures no aspect of a patient’s condition is overlooked and promotes shared decision-making.
Why an MDT Review Matters in Cannabis Clinics
Medical cannabis remains a relatively new therapy in the UK since regulations changed in November 2018. Despite growing interest, it involves challenges:
- Use of unlicensed medicines: Most cannabis-based products are unlicensed, meaning they lack full regulatory approval for specific indications. Complex conditions: Patients often seek cannabis for multifaceted problems like chronic pain, epilepsy, or mental health conditions. Prescribing risk: Doctors must carefully assess benefits and harms and comply with legal and ethical frameworks. Specialist competence: Not every doctor has training or experience prescribing cannabis-based products safely.
Given these factors, an MDT review can help ensure that cannabis prescribing is appropriate, supported by expertise, and carefully monitored.
Regulation and Clinic Oversight
UK healthcare providers, including private cannabis clinics, fall under the scrutiny of the Care Quality Commission (CQC). The CQC requires that clinics provide safe, effective, and well-led care. Part of this includes having systems in place for clinical governance – which often involves MDT discussions for difficult cases.
While a formal MDT review might not be explicitly mandated, the principles behind it support compliance with CQC standards: thorough risk assessment, multidisciplinary input, and documented decision-making. Clinics that skip this process increase the risk of unsafe prescribing and may fall short of regulatory expectations.
Unlicensed Medicines and Risk Disclosure
Medical cannabis products are mostly unlicensed in the UK. This status means there's less comprehensive data on efficacy and safety, increasing reliance on clinical judgment and patient dialogue.
Clinics must disclose these risks transparently to patients. An MDT case review adds another layer of safety by pooling expertise to scrutinize whether cannabis is a suitable treatment option, what dosages and products might be best, and how to manage side effects or interactions. ...where was I going with this?
Who Is Legally Allowed to Prescribe Cannabis?
Only doctors on the General Medical Council (GMC) Specialist Register or fully licensed general practitioners can prescribe cannabis-based products. This restricts prescribing to clinicians who have demonstrated competence in their specialty.
In cannabis clinics, it's crucial that the prescribing doctor is registered, qualified, and ideally has relevant experience or training in complex symptom management or pain medicine. The MDT review can involve specialists who are registered and bring appropriate knowledge to the table.
Specialist Competence and Scope
Pain specialists, neurologists, psychiatrists, and palliative care consultants are often better equipped to assess and manage cannabis therapy than generalists without specialist insight.
When a clinic advertises “specialist doctors” but refuses to name them or their GMC registration numbers, that’s a red flag. Patients should always:
- Ask for the prescribing doctor’s GMC registration number. Check their status on the GMC Specialist Register. Confirm the clinic’s CQC registration and compliance.
MDT reviews often include such specialists, ensuring prescribing occurs within a safe and competent framework.
Does Your Cannabis Clinic Need an MDT Review?
Short answer: Yes, if you want to provide safe, compliant, and effective care for complex conditions.
Here are some signs your clinic needs to implement or strengthen MDT case review processes:
- You prescribe cannabis-based products for patients with multiple comorbidities or complex symptoms. You use unlicensed medicines regularly and need to manage informed consent and risk disclosure rigorously. You want to satisfy CQC’s standards for clinical governance, safety, and leadership. You wish to involve specialists registered with the GMC to support your prescribing decisions. You aim to provide clear documentation and accountability for patient case management.
While smaller clinics may find setting up formal MDT meetings challenging, even a limited case review process involving at least two clinicians can reduce risks and improve quality.
Questions Patients Should Ask Their Clinic About MDT Reviews
Question Why It Matters What is your clinic’s registration number with the CQC? Confirms the clinic is inspected and regulated. Do you have a formal case review process or MDT meetings for your patients? Shows how complex cases and risks are managed. Who prescribes my cannabis medicine, and what are their GMC registration details? Ensures prescribing is by a qualified and competent doctor. Do you involve specialists registered on the GMC Specialist Register? Indicates the presence of relevant expertise. How are risks and uncertainties of unlicensed cannabis discussed with patients? Reflects informed consent and transparency.Conclusion
An MDT review is more than a buzzword—it's a crucial part of managing complex patients safely and effectively, particularly when unlicensed medicines like medical cannabis are involved. For UK cannabis clinics, adopting structured multidisciplinary case reviews enhances clinical governance, reassures regulators like the CQC, and most importantly, protects patient safety.
Patients should feel empowered to ask their cannabis clinic about MDT reviews, the qualifications of prescribing doctors, and how they manage the challenges posed by complex conditions and unlicensed therapies. Transparency and specialist competence are pillars of safe cannabis prescribing.
If your cannabis clinic doesn’t have an MDT review process yet, now is the time to develop one. It’s not only a mark of good quality care but a practical necessity in today’s regulated healthcare environment.